Koers Regulus Therapeutics Inc Nasdaq
Aandelen
US75915K1016
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 158 mln. 148 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -33 mln. -30,86 mln. | Nettowinst (verlies) 2025 * | -46 mln. -43,02 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 94,2 mln. 88,1 mln. | Nettoliquiditeiten 2025 * | 50,8 mln. 47,51 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-4,77
x | K/w-verhouding 2025 * |
-3,97
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 95,99% |
Recentste transcriptie over Regulus Therapeutics Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 04-01-16 |
Preston Klassen
PSD | President | 55 | 22-06-23 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 30-08-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 01-06-17 |
David Baltimore
BRD | Director/Board Member | 86 | 01-01-09 |
Director/Board Member | 75 | 01-04-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |